The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2021 | Treatment of early-stage CTCL
Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, gives an overview of the treatment of early-stage cutaneous T-cell lymphoma (CTCL), highlighting the use of locally-intensive therapies and commenting on the need to develop therapies which target symptoms. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
